Charles River Laboratories International, Inc. CRL

What this company does

Charles River Laboratories provides discovery and safety assessment services, both Good Laboratory Practice and non-GLP, that support clients from target identification through non-clinical development, and provides products and services to support clients' manufacturing activities. It currently operates in over 120 sites and in over 20 countries worldwide, excluding certain Insourcing Solutions sites. In 2025, its total revenue was $4.0 billion. It has three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). In 2025, RMS accounted for 21.1% of its total revenue and approximately 4,140 of its employees, including approximately 190 science professionals with advanced degrees. In 2025, its DSA segment represented 59.8% of its total revenue and employed approximately 11,760 of its employees, including approximately 1,680 science professionals with advanced degrees. In 2025, Manufacturing accounted for 19.1% of its total revenue and approximately 2,600 of its employees, including approximately 350 science professionals with advanced degrees. Through its RMS segment, it has provided foundational tools for the discovery of new molecules by supplying research models to the drug development industry since 1947.

Written from the business description in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.